100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R44AI141283
Award Date
8/15/18
Completion Date
3/31/27
Dollars Obligated
$7.9M
Overview
Activity
16
Transactions
16
Subawards
Similar Awards
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Prothera Biologics, Inc. (ZAE3CABBMZE9)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Providence, RI 02903, USA
Update #1
Update #2
RAPID TEST TO ASSIST THERAPY IN NEONATAL SEPSIS AND NECROTIZING ENTEROCOLITIS
Posted 8/14/18
5
1
2
3
4
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
RAPID TEST TO ASSIST THERAPY IN NEONATAL SEPSIS AND NECROTIZING ENTEROCOLITIS - THE PRIMARY GOAL OF THIS PROPOSED RESEARCH IS TO DEVELOP A RAPID POINT-OF-CARE (POC) TEST, BASED ON INTER-ALPHA INHIBITOR PROTEINS (IAIP) LEVELS IN BLOOD, THAT ASSESSES THE RISK OF NEONATAL SEPSIS (NS) AND/OR NECROTIZING ENTEROCOLITIS (NEC) IN INFANTS. NS AND NEC ARE ASSOCIATED WITH HIGH MORTALITY, SERIOUS MORBIDITY, AND ADVERSE NEURO-DEVELOPMENTAL OUTCOMES. THE CURRENTLY AVAILABLE BIOMARKERS ARE NOT SENSITIVE AND SPECIFIC ENOUGH FOR EARLY DETECTION OF NS AND NEC TO RELIABLY GUIDE CLINICAL DECISIONS FOR CONTINUATION OF ANTIBIOTIC TREATMENT IN INFANTS WHOSE CONVENTIONAL TEST RESULTS ARE UNINFORMATIVE. IAIP ARE FOUND IN HUMAN PLASMA AT HIGH CONCENTRATIONS AND ARE RAPIDLY DEPLETED DURING ACUTE SEVERE INFECTION/SYSTEMIC INFLAMMATION. IN THE RECENTLY COMPLETED SBIR PHASE II STUDY, WE SUCCESSFULLY DEVELOPED A PROTOTYPE FOR A RAPID TEST (RT) THAT ACCURATELY MEASURES THE IAIP LEVEL IN BLOOD WITHIN 15 MINUTES, WITH COMPARABLE RESULTS TO A 6-HOUR LABORATORY ELISA. USING THE NEWLY DEVELOPED RT, WE CONFIRMED THAT IAIP LEVEL IS A SENSITIVE AND SPECIFIC PREDICTIVE MARKER FOR NS AND NEC USING BLOOD SAMPLES COLLECTED FROM ENROLLED INFANTS IN TWO QUATERNARY CARE NICUS. THE AUC OF THE ROC ANALYSIS COMPARING INFANTS WITH POSITIVE AND NEGATIVE BLOOD CULTURES WAS 0.991 AND THE SENSITIVITY OF 96.3% AND SPECIFICITY OF 94.6% (P2) AND IAIP IS MORE SENSITIVE THAN PCT AND CRP IN DETECTING NS AND NEC IN SUSPECTED INFANTS THAT ARE NOT CONFIRMED BY BLOOD CULTURE OR RADIOGRAPHS. THE IAIP LEVEL WILL REMAIN NORMAL OR NOT BE SIGNIFICANTLY ALTERED DURING NON-INFECTIOUS/NON-SYSTEMIC DISTURBANCES THAT GENERALLY DO NOT WARRANT ANTIBIOTIC TREATMENT. THE IAIP-RT WOULD BE USEFUL IN REDUCING EXPOSURE TO UNNECESSARY LONG-TERM, BROAD-SPECTRUM ANTIBIOTICS TO THESE INFANTS. THE SPECIFIC AIMS ARE: 1) PROCESS VALIDATION AND SCALE-UP MANUFACTURING TO PRODUCE CLINICAL-GRADE IAIP-RT BATCHES FOR IMPLEMENTATION OF REGULATORY STRATEGY; 2) CONFIRM AND VALIDATE THE ROC CHARACTERISTICS AND CUT-OFF VALUE OF THE IAIP-RT IN LARGER CLINICAL SAMPLES OF NS AND NEC; 3A) PERFORM A COMPARISON STUDY OF IAIP TEST HEAD-TO-HEAD WITH PCT AND CRP DURING CLINICAL EVALUATION OF NS AND NEC; 3B) ASSESS THE POTENTIAL FOR ANTIBIOTIC DISCONTINUATION IN INFANTS WITH NEGATIVE BLOOD CULTURE, NEGATIVE NEC SYMPTOMS AND NORMAL IAIP LEVEL AND 4) COMPARE THE NATURAL HISTORY OF LONGITUDINALLY COLLECTED IAIP LEVELS WITH CLINICAL COURSE AND OUTCOME. THESE STUDIES ARE DESIGNED TO OBTAIN A ROBUST AND FULLY DEVELOPED POC DEVICE TO MEASURE IAIP LEVELS IN INFANTS THAT IS READY FOR FUTURE CLINICAL STUDIES REQUIRED FOR FDA APPROVAL.
$0
7/17/26
Not listed
RAPID TEST TO ASSIST THERAPY IN NEONATAL SEPSIS AND NECROTIZING ENTEROCOLITIS - THE PRIMARY GOAL OF THIS PROPOSED RESEARCH IS TO DEVELOP A RAPID POINT-OF-CARE (POC) TEST, BASED ON INTER-ALPHA INHIBITOR PROTEINS (IAIP) LEVELS IN BLOOD, THAT ASSESSES THE RISK OF NEONATAL SEPSIS (NS) AND/OR NECROTIZING ENTEROCOLITIS (NEC) IN INFANTS. NS AND NEC ARE ASSOCIATED WITH HIGH MORTALITY, SERIOUS MORBIDITY, AND ADVERSE NEURO-DEVELOPMENTAL OUTCOMES. THE CURRENTLY AVAILABLE BIOMARKERS ARE NOT SENSITIVE AND SPECIFIC ENOUGH FOR EARLY DETECTION OF NS AND NEC TO RELIABLY GUIDE CLINICAL DECISIONS FOR CONTINUATION OF ANTIBIOTIC TREATMENT IN INFANTS WHOSE CONVENTIONAL TEST RESULTS ARE UNINFORMATIVE. IAIP ARE FOUND IN HUMAN PLASMA AT HIGH CONCENTRATIONS AND ARE RAPIDLY DEPLETED DURING ACUTE SEVERE INFECTION/SYSTEMIC INFLAMMATION. IN THE RECENTLY COMPLETED SBIR PHASE II STUDY, WE SUCCESSFULLY DEVELOPED A PROTOTYPE FOR A RAPID TEST (RT) THAT ACCURATELY MEASURES THE IAIP LEVEL IN BLOOD WITHIN 15 MINUTES, WITH COMPARABLE RESULTS TO A 6-HOUR LABORATORY ELISA. USING THE NEWLY DEVELOPED RT, WE CONFIRMED THAT IAIP LEVEL IS A SENSITIVE AND SPECIFIC PREDICTIVE MARKER FOR NS AND NEC USING BLOOD SAMPLES COLLECTED FROM ENROLLED INFANTS IN TWO QUATERNARY CARE NICUS. THE AUC OF THE ROC ANALYSIS COMPARING INFANTS WITH POSITIVE AND NEGATIVE BLOOD CULTURES WAS 0.991 AND THE SENSITIVITY OF 96.3% AND SPECIFICITY OF 94.6% (P2) AND IAIP IS MORE SENSITIVE THAN PCT AND CRP IN DETECTING NS AND NEC IN SUSPECTED INFANTS THAT ARE NOT CONFIRMED BY BLOOD CULTURE OR RADIOGRAPHS. THE IAIP LEVEL WILL REMAIN NORMAL OR NOT BE SIGNIFICANTLY ALTERED DURING NON-INFECTIOUS/NON-SYSTEMIC DISTURBANCES THAT GENERALLY DO NOT WARRANT ANTIBIOTIC TREATMENT. THE IAIP-RT WOULD BE USEFUL IN REDUCING EXPOSURE TO UNNECESSARY LONG-TERM, BROAD-SPECTRUM ANTIBIOTICS TO THESE INFANTS. THE SPECIFIC AIMS ARE: 1) PROCESS VALIDATION AND SCALE-UP MANUFACTURING TO PRODUCE CLINICAL-GRADE IAIP-RT BATCHES FOR IMPLEMENTATION OF REGULATORY STRATEGY; 2) CONFIRM AND VALIDATE THE ROC CHARACTERISTICS AND CUT-OFF VALUE OF THE IAIP-RT IN LARGER CLINICAL SAMPLES OF NS AND NEC; 3A) PERFORM A COMPARISON STUDY OF IAIP TEST HEAD-TO-HEAD WITH PCT AND CRP DURING CLINICAL EVALUATION OF NS AND NEC; 3B) ASSESS THE POTENTIAL FOR ANTIBIOTIC DISCONTINUATION IN INFANTS WITH NEGATIVE BLOOD CULTURE, NEGATIVE NEC SYMPTOMS AND NORMAL IAIP LEVEL AND 4) COMPARE THE NATURAL HISTORY OF LONGITUDINALLY COLLECTED IAIP LEVELS WITH CLINICAL COURSE AND OUTCOME. THESE STUDIES ARE DESIGNED TO OBTAIN A ROBUST AND FULLY DEVELOPED POC DEVICE TO MEASURE IAIP LEVELS IN INFANTS THAT IS READY FOR FUTURE CLINICAL STUDIES REQUIRED FOR FDA APPROVAL.
$954.2k
5/13/26
Not listed
RAPID TEST TO ASSIST THERAPY IN NEONATAL SEPSIS AND NECROTIZING ENTEROCOLITIS - THE PRIMARY GOAL OF THIS PROPOSED RESEARCH IS TO DEVELOP A RAPID POINT-OF-CARE (POC) TEST, BASED ON INTER-ALPHA INHIBITOR PROTEINS (IAIP) LEVELS IN BLOOD, THAT ASSESSES THE RISK OF NEONATAL SEPSIS (NS) AND/OR NECROTIZING ENTEROCOLITIS (NEC) IN INFANTS. NS AND NEC ARE ASSOCIATED WITH HIGH MORTALITY, SERIOUS MORBIDITY, AND ADVERSE NEURO-DEVELOPMENTAL OUTCOMES. THE CURRENTLY AVAILABLE BIOMARKERS ARE NOT SENSITIVE AND SPECIFIC ENOUGH FOR EARLY DETECTION OF NS AND NEC TO RELIABLY GUIDE CLINICAL DECISIONS FOR CONTINUATION OF ANTIBIOTIC TREATMENT IN INFANTS WHOSE CONVENTIONAL TEST RESULTS ARE UNINFORMATIVE. IAIP ARE FOUND IN HUMAN PLASMA AT HIGH CONCENTRATIONS AND ARE RAPIDLY DEPLETED DURING ACUTE SEVERE INFECTION/SYSTEMIC INFLAMMATION. IN THE RECENTLY COMPLETED SBIR PHASE II STUDY, WE SUCCESSFULLY DEVELOPED A PROTOTYPE FOR A RAPID TEST (RT) THAT ACCURATELY MEASURES THE IAIP LEVEL IN BLOOD WITHIN 15 MINUTES, WITH COMPARABLE RESULTS TO A 6-HOUR LABORATORY ELISA. USING THE NEWLY DEVELOPED RT, WE CONFIRMED THAT IAIP LEVEL IS A SENSITIVE AND SPECIFIC PREDICTIVE MARKER FOR NS AND NEC USING BLOOD SAMPLES COLLECTED FROM ENROLLED INFANTS IN TWO QUATERNARY CARE NICUS. THE AUC OF THE ROC ANALYSIS COMPARING INFANTS WITH POSITIVE AND NEGATIVE BLOOD CULTURES WAS 0.991 AND THE SENSITIVITY OF 96.3% AND SPECIFICITY OF 94.6% (P2) AND IAIP IS MORE SENSITIVE THAN PCT AND CRP IN DETECTING NS AND NEC IN SUSPECTED INFANTS THAT ARE NOT CONFIRMED BY BLOOD CULTURE OR RADIOGRAPHS. THE IAIP LEVEL WILL REMAIN NORMAL OR NOT BE SIGNIFICANTLY ALTERED DURING NON-INFECTIOUS/NON-SYSTEMIC DISTURBANCES THAT GENERALLY DO NOT WARRANT ANTIBIOTIC TREATMENT. THE IAIP-RT WOULD BE USEFUL IN REDUCING EXPOSURE TO UNNECESSARY LONG-TERM, BROAD-SPECTRUM ANTIBIOTICS TO THESE INFANTS. THE SPECIFIC AIMS ARE: 1) PROCESS VALIDATION AND SCALE-UP MANUFACTURING TO PRODUCE CLINICAL-GRADE IAIP-RT BATCHES FOR IMPLEMENTATION OF REGULATORY STRATEGY; 2) CONFIRM AND VALIDATE THE ROC CHARACTERISTICS AND CUT-OFF VALUE OF THE IAIP-RT IN LARGER CLINICAL SAMPLES OF NS AND NEC; 3A) PERFORM A COMPARISON STUDY OF IAIP TEST HEAD-TO-HEAD WITH PCT AND CRP DURING CLINICAL EVALUATION OF NS AND NEC; 3B) ASSESS THE POTENTIAL FOR ANTIBIOTIC DISCONTINUATION IN INFANTS WITH NEGATIVE BLOOD CULTURE, NEGATIVE NEC SYMPTOMS AND NORMAL IAIP LEVEL AND 4) COMPARE THE NATURAL HISTORY OF LONGITUDINALLY COLLECTED IAIP LEVELS WITH CLINICAL COURSE AND OUTCOME. THESE STUDIES ARE DESIGNED TO OBTAIN A ROBUST AND FULLY DEVELOPED POC DEVICE TO MEASURE IAIP LEVELS IN INFANTS THAT IS READY FOR FUTURE CLINICAL STUDIES REQUIRED FOR FDA APPROVAL.
$954.2k
5/13/26
Not listed
RAPID TEST TO ASSIST THERAPY IN NEONATAL SEPSIS AND NECROTIZING ENTEROCOLITIS - THE PRIMARY GOAL OF THIS PROPOSED RESEARCH IS TO DEVELOP A RAPID POINT-OF-CARE (POC) TEST, BASED ON INTER-ALPHA INHIBITOR PROTEINS (IAIP) LEVELS IN BLOOD, THAT ASSESSES THE RISK OF NEONATAL SEPSIS (NS) AND/OR NECROTIZING ENTEROCOLITIS (NEC) IN INFANTS. NS AND NEC ARE ASSOCIATED WITH HIGH MORTALITY, SERIOUS MORBIDITY, AND ADVERSE NEURO-DEVELOPMENTAL OUTCOMES. THE CURRENTLY AVAILABLE BIOMARKERS ARE NOT SENSITIVE AND SPECIFIC ENOUGH FOR EARLY DETECTION OF NS AND NEC TO RELIABLY GUIDE CLINICAL DECISIONS FOR CONTINUATION OF ANTIBIOTIC TREATMENT IN INFANTS WHOSE CONVENTIONAL TEST RESULTS ARE UNINFORMATIVE. IAIP ARE FOUND IN HUMAN PLASMA AT HIGH CONCENTRATIONS AND ARE RAPIDLY DEPLETED DURING ACUTE SEVERE INFECTION/SYSTEMIC INFLAMMATION. IN THE RECENTLY COMPLETED SBIR PHASE II STUDY, WE SUCCESSFULLY DEVELOPED A PROTOTYPE FOR A RAPID TEST (RT) THAT ACCURATELY MEASURES THE IAIP LEVEL IN BLOOD WITHIN 15 MINUTES, WITH COMPARABLE RESULTS TO A 6-HOUR LABORATORY ELISA. USING THE NEWLY DEVELOPED RT, WE CONFIRMED THAT IAIP LEVEL IS A SENSITIVE AND SPECIFIC PREDICTIVE MARKER FOR NS AND NEC USING BLOOD SAMPLES COLLECTED FROM ENROLLED INFANTS IN TWO QUATERNARY CARE NICUS. THE AUC OF THE ROC ANALYSIS COMPARING INFANTS WITH POSITIVE AND NEGATIVE BLOOD CULTURES WAS 0.991 AND THE SENSITIVITY OF 96.3% AND SPECIFICITY OF 94.6% (P2) AND IAIP IS MORE SENSITIVE THAN PCT AND CRP IN DETECTING NS AND NEC IN SUSPECTED INFANTS THAT ARE NOT CONFIRMED BY BLOOD CULTURE OR RADIOGRAPHS. THE IAIP LEVEL WILL REMAIN NORMAL OR NOT BE SIGNIFICANTLY ALTERED DURING NON-INFECTIOUS/NON-SYSTEMIC DISTURBANCES THAT GENERALLY DO NOT WARRANT ANTIBIOTIC TREATMENT. THE IAIP-RT WOULD BE USEFUL IN REDUCING EXPOSURE TO UNNECESSARY LONG-TERM, BROAD-SPECTRUM ANTIBIOTICS TO THESE INFANTS. THE SPECIFIC AIMS ARE: 1) PROCESS VALIDATION AND SCALE-UP MANUFACTURING TO PRODUCE CLINICAL-GRADE IAIP-RT BATCHES FOR IMPLEMENTATION OF REGULATORY STRATEGY; 2) CONFIRM AND VALIDATE THE ROC CHARACTERISTICS AND CUT-OFF VALUE OF THE IAIP-RT IN LARGER CLINICAL SAMPLES OF NS AND NEC; 3A) PERFORM A COMPARISON STUDY OF IAIP TEST HEAD-TO-HEAD WITH PCT AND CRP DURING CLINICAL EVALUATION OF NS AND NEC; 3B) ASSESS THE POTENTIAL FOR ANTIBIOTIC DISCONTINUATION IN INFANTS WITH NEGATIVE BLOOD CULTURE, NEGATIVE NEC SYMPTOMS AND NORMAL IAIP LEVEL AND 4) COMPARE THE NATURAL HISTORY OF LONGITUDINALLY COLLECTED IAIP LEVELS WITH CLINICAL COURSE AND OUTCOME. THESE STUDIES ARE DESIGNED TO OBTAIN A ROBUST AND FULLY DEVELOPED POC DEVICE TO MEASURE IAIP LEVELS IN INFANTS THAT IS READY FOR FUTURE CLINICAL STUDIES REQUIRED FOR FDA APPROVAL.
$971.3k
4/25/25
Not listed
RAPID TEST TO ASSIST THERAPY IN NEONATAL SEPSIS AND NECROTIZING ENTEROCOLITIS - THE PRIMARY GOAL OF THIS PROPOSED RESEARCH IS TO DEVELOP A RAPID POINT-OF-CARE (POC) TEST, BASED ON INTER-ALPHA INHIBITOR PROTEINS (IAIP) LEVELS IN BLOOD, THAT ASSESSES THE RISK OF NEONATAL SEPSIS (NS) AND/OR NECROTIZING ENTEROCOLITIS (NEC) IN INFANTS. NS AND NEC ARE ASSOCIATED WITH HIGH MORTALITY, SERIOUS MORBIDITY, AND ADVERSE NEURO-DEVELOPMENTAL OUTCOMES. THE CURRENTLY AVAILABLE BIOMARKERS ARE NOT SENSITIVE AND SPECIFIC ENOUGH FOR EARLY DETECTION OF NS AND NEC TO RELIABLY GUIDE CLINICAL DECISIONS FOR CONTINUATION OF ANTIBIOTIC TREATMENT IN INFANTS WHOSE CONVENTIONAL TEST RESULTS ARE UNINFORMATIVE. IAIP ARE FOUND IN HUMAN PLASMA AT HIGH CONCENTRATIONS AND ARE RAPIDLY DEPLETED DURING ACUTE SEVERE INFECTION/SYSTEMIC INFLAMMATION. IN THE RECENTLY COMPLETED SBIR PHASE II STUDY, WE SUCCESSFULLY DEVELOPED A PROTOTYPE FOR A RAPID TEST (RT) THAT ACCURATELY MEASURES THE IAIP LEVEL IN BLOOD WITHIN 15 MINUTES, WITH COMPARABLE RESULTS TO A 6-HOUR LABORATORY ELISA. USING THE NEWLY DEVELOPED RT, WE CONFIRMED THAT IAIP LEVEL IS A SENSITIVE AND SPECIFIC PREDICTIVE MARKER FOR NS AND NEC USING BLOOD SAMPLES COLLECTED FROM ENROLLED INFANTS IN TWO QUATERNARY CARE NICUS. THE AUC OF THE ROC ANALYSIS COMPARING INFANTS WITH POSITIVE AND NEGATIVE BLOOD CULTURES WAS 0.991 AND THE SENSITIVITY OF 96.3% AND SPECIFICITY OF 94.6% (P2) AND IAIP IS MORE SENSITIVE THAN PCT AND CRP IN DETECTING NS AND NEC IN SUSPECTED INFANTS THAT ARE NOT CONFIRMED BY BLOOD CULTURE OR RADIOGRAPHS. THE IAIP LEVEL WILL REMAIN NORMAL OR NOT BE SIGNIFICANTLY ALTERED DURING NON-INFECTIOUS/NON-SYSTEMIC DISTURBANCES THAT GENERALLY DO NOT WARRANT ANTIBIOTIC TREATMENT. THE IAIP-RT WOULD BE USEFUL IN REDUCING EXPOSURE TO UNNECESSARY LONG-TERM, BROAD-SPECTRUM ANTIBIOTICS TO THESE INFANTS. THE SPECIFIC AIMS ARE: 1) PROCESS VALIDATION AND SCALE-UP MANUFACTURING TO PRODUCE CLINICAL-GRADE IAIP-RT BATCHES FOR IMPLEMENTATION OF REGULATORY STRATEGY; 2) CONFIRM AND VALIDATE THE ROC CHARACTERISTICS AND CUT-OFF VALUE OF THE IAIP-RT IN LARGER CLINICAL SAMPLES OF NS AND NEC; 3A) PERFORM A COMPARISON STUDY OF IAIP TEST HEAD-TO-HEAD WITH PCT AND CRP DURING CLINICAL EVALUATION OF NS AND NEC; 3B) ASSESS THE POTENTIAL FOR ANTIBIOTIC DISCONTINUATION IN INFANTS WITH NEGATIVE BLOOD CULTURE, NEGATIVE NEC SYMPTOMS AND NORMAL IAIP LEVEL AND 4) COMPARE THE NATURAL HISTORY OF LONGITUDINALLY COLLECTED IAIP LEVELS WITH CLINICAL COURSE AND OUTCOME. THESE STUDIES ARE DESIGNED TO OBTAIN A ROBUST AND FULLY DEVELOPED POC DEVICE TO MEASURE IAIP LEVELS IN INFANTS THAT IS READY FOR FUTURE CLINICAL STUDIES REQUIRED FOR FDA APPROVAL.
$0
5/15/24